Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190367 | 1.00 | — | — | |
| SCHEMBL1190324 | 1.00 | — | — | |
| SCHEMBL1190325 | 1.00 | — | — | |
| SCHEMBL1190366 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30106556 | 0.96 | — | — | |
| SCHEMBL8698710 | 0.89 | HIF1A (0.43) | ALPLL3MBTL1MAPT | |
| SCHEMBL8698714 | 0.89 | HIF1A (0.43) | ALPLL3MBTL1MAPT | |
| SCHEMBL8631773 | 0.89 | HIF1A (0.43) | ALPLL3MBTL1MAPT | |
| SCHEMBL8229546 | 0.89 | HIF1A (0.43) | ALPLL3MBTL1MAPT | |
| SCHEMBL14407774 | 0.89 | HIF1A (0.43) | ALPLL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196500-A1 | Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-07-16 | — | — | US | disclosed |
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | TFAM, NDUFAB1, HSPA9 | ALPL 3920/4885L3MBTL1 2316/4885FUCA1 3415/4885 |
| US-20150196500-A1 | Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits | TFAM, NDUFAB1, HSPA9 | ALPL 3920/4885L3MBTL1 2316/4885FUCA1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.